Clinical Trial Detail

NCT ID NCT02331368
Title Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

multiple myeloma

Therapies

Lenalidomide

Melphalan

Pembrolizumab

Age Groups: adult

No variant requirements are available.